Table 3.

Rechallenging immune-checkpoint inhibitors and prevention of immune-related adverse events.

Rechallenge	Class switch: PD-1/PD-L1 to CTLA4, vice versa (43, 138)
	Resume same agent: After complete recovery from irAE (34, 135, 139)
	Drop CTLA4 agent: In patients who had irAE with CTLA4 and PD-1 combination (140)
Prevention	Testing inflammatory markers such as lactoferrin and calprotectin in patients with ≥ grade 2 diarrhea
	For the patient with grade 1 hepatitis, liver chemistries must be repeated 1-2 times/week
	For patients with G2 hepatitis, therapy must be held until resolution to G1